Table 3.
Demographic and clinical information in children positive for novel coronavirus disease (COVID-19) who had medical imaging and comorbidities
| Variables (n=55) | n (%) |
|---|---|
| Age, years, median (IQR) | 9 (12) |
| Gender | |
| Girls | 29 (53%) |
| Boys | 26 (47%) |
| PICU | 17 (31%) |
| Ventilation assistance | 14 (25%) |
| Asymptomatic | 11 (20%) |
| Symptomatic | 44 (80%) |
| Number of comorbidities per patient | |
| None | 14 (25%) |
| One comorbidity | 13 (24%) |
| Two comorbidities | 4 (7%) |
| Three or more comorbidities | 26 (47%) |
| Comorbiditiesa | |
| Acute lymphoblastic anemia | 2 (4%) |
| Adrenal insufficiency | 1 (2%) |
| Anemia | 3 (5%) |
| Anxiety/depression | 4 (7%) |
| Asthma | 7 (13%) |
| Autism | 1 (2%) |
| Cardiomyopathy | 2 (4%) |
| Cerebral venous thrombosis | 1 (2%) |
| Chronic lung disease | 1 (2%) |
| Congenital diaphragmatic hernia | 1 (2%) |
| Congenital heart disease | 3 (5%) |
| Croup | 1 (2%) |
| Epilepsy | 3 (5%) |
| Gastroesophageal reflux disease | 3 (5%) |
| Gastrointestinal disease | 2 (4%) |
| Glucose-6-phosphate dehydrogenase deficiency | 2 (4%) |
| Gray matter heterotopia | 1 (2%) |
| G-tube | 4 (7%) |
| Hypertension | 1 (2%) |
| Mediastinal ganglioneuroblastoma | 1 (2%) |
| MRSA bacteremia | 1 (2%) |
| Neurofibromatosis Type 1 | 2 (4%) |
| Neurologic impairment/infection | 4 (7%) |
| Obesity | 2 (4%) |
| Osteomyelitis | 3 (5%) |
| Osteosarcoma | 1 (2%) |
| History of pulmonary embolism | 2 (4%) |
| Renal disease | 3 (5%) |
| Sepsis | 3 (5%) |
| Short gut syndrome | 1 (2%) |
| Sickle cell disease | 2 (4%) |
| Stroke | 1 (2%) |
| Tracheomalacia | 1 (2%) |
| Trisomy 21 | 1 (2%) |
| Type 2 diabetes mellitus | 2 (4%) |
| Valvulopathy | 1 (2%) |
G-tube gastrostomy tube, IQR interquartile range, PICU pediatric intensive care unit, MRSA methicillin-resistant Staphylococcus aureus
aNumber of children with the specific comorbidity; some children had more than one comorbidity